{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:20:34Z","timestamp":1791181234881,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/ajg.2014.106","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T07:59:12Z","timestamp":1399363152000},"page":"1055-1064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial"],"prefix":"10.14309","volume":"109","author":[{"given":"Casper","family":"Steenholdt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Bendtzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Brynskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole \u00d8","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Ainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210210","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohns disease in adults.","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R2-21-20210210","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R3-21-20210210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohns disease: Current management.","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R4-21-20210210","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohns and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"DHaens","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R5-21-20210210","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults.","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"key":"R7-21-20210210","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","article-title":"A test-based strategy is more cost effective than empiric dose escalation for patients with Crohns disease who lose responsiveness to infliximab.","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-21-20210210","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"R9-21-20210210","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12407","article-title":"Review article: a clinicians guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.","volume":"38","author":"Khanna","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-21-20210210","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.","volume":"10","author":"Ordas","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R12-21-20210210","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ibd.22910","article-title":"Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.","volume":"18","author":"Steenholdt","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R13-21-20210210","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ajg.2013.12","article-title":"Antibody response to infliximab and its impact on pharmacokinetics can be transient.","volume":"108","author":"Vande","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R14-21-20210210","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohns disease.","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-21-20210210","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.","volume":"91","author":"Ordas","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R16-21-20210210","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R17-21-20210210","first-page":"201","article-title":"Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists.","volume":"15","author":"Bendtzen","year":"2013","journal-title":"Discov Med"},{"key":"R18-21-20210210","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/imt.12.114","article-title":"Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine.","volume":"4","author":"Bendtzen","year":"2012","journal-title":"Immunotherapy"},{"key":"R19-21-20210210","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2012.05057.x","article-title":"Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease.","volume":"35","author":"Chaparro","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-21-20210210","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/FTD.0b013e31828d23c3","article-title":"Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohns disease.","volume":"35","author":"Steenholdt","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R21-21-20210210","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohns disease.","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"R22-21-20210210","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease.","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"R23-21-20210210","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R24-21-20210210","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","article-title":"Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.","volume":"46","author":"Svenson","year":"2007","journal-title":"Rheumatology"},{"key":"R25-21-20210210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.","volume":"382","author":"Wang","year":"2012","journal-title":"J Immunol Methods"},{"key":"R26-21-20210210","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists.","volume":"373","author":"Lallemand","year":"2011","journal-title":"J Immunol Methods"},{"key":"R29-21-20210210","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R30-21-20210210","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/MEG.0b013e32835558cf","article-title":"Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.","volume":"24","author":"Lee","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R31-21-20210210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R32-21-20210210","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.","volume":"36","author":"Vande","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-21-20210210","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R34-21-20210210","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/ard.2011.153023","article-title":"Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.","volume":"70","author":"Takeuchi","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R35-21-20210210","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/apt.12262","article-title":"The Crohns disease activity index (CDAI) is similarly elevated in patients with Crohns disease and in patients with irritable bowel syndrome.","volume":"37","author":"Lahiff","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-21-20210210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohns disease in the SONIC trial.","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"R37-21-20210210","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0140-6736(00)02871-3","article-title":"Mechanisms in failure of infliximab for Crohns disease.","volume":"356","author":"Nikolaus","year":"2000","journal-title":"Lancet"},{"key":"R38-21-20210210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","article-title":"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.","volume":"70","author":"Jamnitski","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2014106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2014106","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2014106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201407000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:49:21Z","timestamp":1786542561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201407000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2014.106","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}